| What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? | |
| | |
MedLine Citation:
|
PMID: 19210673 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To determine the benefit of starting early chemotherapy with docetaxel (the recommended first-line treatment) for patients with asymptomatic metastatic hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS: Data were analysed from 145 patients with HRPC treated with chemotherapy between February 2000 and June 2002 in one French centre. Eligible patients were categorized into three groups according to the bone pain at baseline, i.e. minimal/no pain, mild, and moderate/severe pain. The primary endpoint was the effect of bone pain on overall survival (OS). RESULTS: Docetaxel was administered to 67% of patients. The risk of death was 1.56 and 2.11 times higher for patients with mild or moderate/severe pain than for those with minimal/no pain (P = 0.027). The median (95% confidence interval (CI)) OS was 23.1 (18.5-27.6) and 14.1 (8.9-19.2) months (P = 0.001, log-rank-test) for patients with minimal pain or no pain treated with docetaxel-based chemotherapy compared with mitoxantrone, respectively. The prostate-specific antigen doubling time (PSA-DT) had a significant effect on OS in patients with minimal/no pain, with a median of 32.4 and 16.5 months for a PSA-DT of >or=45 and <45 days, respectively (P < 0.001). CONCLUSIONS: Our results suggest that patients with HRPC and minimal or no bone pain could have better survival than those with mild pain or moderate to severe pain, independent of the treatment administered. In addition, patients with HRPC and minimal or no bone pain treated with docetaxel-based chemotherapy have a significantly better OS than those treated with mitoxantrone. The PSA-DT can be useful to identify asymptomatic patients who are candidates for early treatment. |
| | |
Authors:
|
Stéphane Oudard; Eugeniu Banu; Jacques Medioni; Florian Scotte; Adela Banu; Eric Levy; Johana Wasserman; Gabriel Kacso; Jean-Marie Andrieu |
Related Documents
:
|
17714103 - Cognitive dysfunction and depression may decrease activities in daily life more strongl... 12939673 - Musculoskeletal pain in the community. 19888033 - Labor pain at the time of epidural analgesia and mode of delivery in nulliparous women ... |
Publication Detail:
|
Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article Date: 2009-02-06 |
Journal Detail:
|
Title: BJU international Volume: 103 ISSN: 1464-410X ISO Abbreviation: BJU Int. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-23 Completed Date: 2009-07-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100886721 Medline TA: BJU Int Country: England |
Other Details:
|
Languages: eng Pagination: 1641-6 Citation Subset: IM |
Affiliation:
|
Medical Oncology Department, Georges Pompidou European Hospital, Paris Rene Descartes University, Paris, France. stephane.oudard@egp.aphp.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Antineoplastic Agents / therapeutic use* Bone Neoplasms / complications, drug therapy*, secondary Cohort Studies Humans Male Middle Aged Mitoxantrone / therapeutic use Pain / etiology* Prognosis Prostate-Specific Antigen / metabolism Prostatic Neoplasms / complications, drug therapy*, mortality Retrospective Studies Severity of Illness Index Survival Analysis Taxoids / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Taxoids; 114977-28-5/docetaxel; 65271-80-9/Mitoxantrone; EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: ANORECTAL MANOMETRY WITH WATER-PERFUSED CATHETER IN HEALTHY ADULTS WITH NO FUNCTIONAL BOWEL DISORDER...
Next Document: Prostate-specific antigen kinetics in localized and advanced prostate cancer.